Abstract | BACKGROUND: METHODS: RESULTS: CONCLUSIONS:
Cediranib at a dose of 20 mg/day and bevacizumab at a dose of 5 mg/kg every 2 weeks was found to be the RP2D. Activity in several tumor types was noted. Central nervous system bleeding and severe hypertension were observed at doses above the RP2D.
|
Authors | David S Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, Gerald S Falchook, Aung Naing, Jennifer J Wheler, Siqing Fu, Stacy L Moulder, Sarina Piha-Paul, Apostolia M Tsimberidou, YueJin Wen, Kirk S Culotta, Kenna Anderes, Darren W Davis, Wen Liu, Goldy C George, Luis H Camacho, Susan Percy Ivy, Razelle Kurzrock |
Journal | Cancer
(Cancer)
Vol. 120
Issue 14
Pg. 2164-73
(Jul 15 2014)
ISSN: 1097-0142 [Electronic] United States |
PMID | 24752867
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 American Cancer Society. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Quinazolines
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Bevacizumab
- cediranib
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
(administration & dosage, adverse effects, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Bevacizumab
- Cerebral Hemorrhage
(chemically induced)
- Drug Administration Schedule
- Female
- Humans
- Hypertension
(chemically induced)
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Neoplasms
(drug therapy, metabolism)
- Neoplastic Cells, Circulating
- Quinazolines
(administration & dosage, adverse effects, therapeutic use)
- Sarcoma
(drug therapy, metabolism)
- Signal Transduction
(drug effects)
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors, metabolism)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|